|
May. 25, 2022 |
|
|
Jan. 22, 2024 |
|
|
jRCT2031220092 |
A single-dose study of HP-6050 |
|
A single-dose study of HP-6050 |
Inakura Hiroshi |
||
Hisamitsu Pharmaceutical Co., Inc. |
||
2-4-1 Marunouchi, Chiyoda-ku, Tokyo |
||
+81-3-5293-1734 |
||
shikenjoho@hisamitsu.co.jp |
||
Clinical Development Department Contact for Clinical Trial Information |
||
Hisamitsu Pharmaceutical Co., Inc. |
||
2-4-1 Marunouchi, Chiyoda-ku, Tokyo |
||
+81-3-5293-1734 |
||
shikenjoho@hisamitsu.co.jp |
Complete |
May. 27, 2022 |
||
| May. 31, 2022 | ||
| 16 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
- Healthy Japanese adult males and females aged >=18 and <40 years |
||
- Subjects with vagal tone |
||
| 18age old over | ||
| 40age old not | ||
Both |
||
Healthy adult |
||
Single dose of HP-6050 |
||
Pharmacokinetic parameters, adverse events |
||
Pharmacodynamics |
||
| Hisamitsu Pharmaceutical Co., Inc. |
| Review Board of Human Rights and Ethics for Clinical Studies | |
| 2-2-1, Kyobashi, Chuo-ku, Tokyo | |
+81-3-5213-0028 |
|
| crb@hurecs.org | |
| Approval | |
May. 27, 2022 |
No |
none |